Vantictumab
Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | Frizzled receptor |
Clinical data | |
Routes of administration | IV |
ATC code |
|
Identifiers | |
CAS Number |
|
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6322H9722N1674O1988S46 |
Molar mass | 142461.81 g·mol−1 |
Vantictumab /vænˈtɪktʊmæb/ is a human IgG2 monoclonal antibody designed for the treatment of cancer.[1]
This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer.[2] OncoMed was awarded a patent in 2016, which is set to expire in 2029.[3] In April 2017, Bayer terminated its option to license vantictumab.[4]
It inhibits wnt signalling by targeting the frizzled receptors on cancer cells.[5]
Phase I trials have been completed for pancreatic cancer, non-small cell lung cancer, and breast cancer. In 2016 results were reported from a phase 1b clinical trial for triple-negative breast cancer.[5]
References[]
- ^ "Statement on a nonproprietary name adopted by the USAN Council" (PDF). AMA. 28 Nov 2012. N12/155.
{{cite web}}
: CS1 maint: url-status (link)(registration required) - ^ "OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance". 12 January 2015.
- ^ http://investor.shareholder.com/oncomed/secfiling.cfm?filingID=1564590-16-14426&CIK=1302573
- ^ "BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept". Reuters. 10 April 2017.
- ^ a b Finally, targeted therapies for triple-negative breast cancer. June 2016
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibody stubs
- Monoclonal antibodies for tumors
- Experimental cancer drugs